Evidence map›Paper›PMID 30925547›Full record

ArticleChinese medical journal2019

Drug resistance and pathogenic spectrum of patients coinfected with nontuberculous mycobacteria and human-immunodeficiency virus in Chengdu, China.

Dong-Mei Wang, Yi Liao, Qing-Feng Li, Ma Zhu, Gui-Hui Wu, Yuan-Hong Xu, Jing Zhong, Jia Luo, Ying-Jie Li

Open access · goldAbstract read
In one paragraph

Article in Chinese medical journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Non-Tuberculous Mycobacterial Diseases in Children.Pathogens (Basel, Switzerland) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Dong-Mei WangDepartment of Clinical Laboratory, Public Health Clinical Center of Chengdu, Chengdu, Sichuan 610066, China.
Yi LiaoDepartment of Clinical Laboratory, Chengdu Woman's and Children's Central Hospital, Chengdu, Sichuan 610073, China.
Qing-Feng LiDepartment of Clinical Laboratory, Public Health Clinical Center of Chengdu, Chengdu, Sichuan 610066, China.
Ma ZhuDepartment of Clinical Laboratory, Public Health Clinical Center of Chengdu, Chengdu, Sichuan 610066, China.
Gui-Hui WuDepartment of Clinical Laboratory, Public Health Clinical Center of Chengdu, Chengdu, Sichuan 610066, China.
Yuan-Hong XuDepartment of Clinical Laboratory, Public Health Clinical Center of Chengdu, Chengdu, Sichuan 610066, China.
Jing ZhongDepartment of Clinical Laboratory, Public Health Clinical Center of Chengdu, Chengdu, Sichuan 610066, China.
Jia LuoDepartment of Clinical Laboratory, Public Health Clinical Center of Chengdu, Chengdu, Sichuan 610066, China.
Ying-Jie LiDepartment of Clinical Laboratory, Public Health Clinical Center of Chengdu, Chengdu, Sichuan 610066, China.
Public Health Clinical Center of Chengdu · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman-immunodeficiency virus (HIV) infection is increasing worldwide and nontuberculous mycobacteria (NTM) is an established microbiologic cause of pulmonary disease, lymphadenitis, and disseminated disease in cases of advanced immune suppression. Data on patients coinfected with HIV and NTM are limited. Thus, this study aimed to analyze the clinical characteristics, drug resistance, and pathogen spectrum of patients coinfected with both HIV and NTM in the Chengdu area of China.

methodsData of 59 patients coinfected with both HIV and NTM collected from the Public Health Clinical Center of Chengdu, between January 2014 and December 2018, were analyzed. NTM drug sensitivity testing was performed using the microporous plate ratio method. Data were analyzed using SPSS 19.0, and the change in drug resistance rate was analyzed using the chi-square (χ) test.

resultsSeven species/complex of NTM were identified from patients coinfected with HIV and NTM in this study, with Mycobacterium avium-intracellulare complex (52.5%) and M. kansasii (27.1%) as the predominant species. Male patients were more affected 50/59 (84.7%); the mean age of the 59 cases was 45 years. The clinical characteristics mainly included anemia (86.4%), cough and expectoration (79.7%). The baseline CD4 count was <50 cells/μL (84.7%). Patients were mainly in advanced acquired immunodeficiency syndrome (AIDS) stage. Chest imaging mainly showed patchy shadows (42.4%) and nodules (32.2%), with various degrees of AIDS-defining diseases. The drug resistance of NTM was severe, and the rate of isoniazid resistance (100.0%) was the highest, followed by rifampicin (94.9%), streptomycin (94.9%), ofloxacin (93.2%), and others. Ethambutol (52.5%) and clarithromycin (33.9%) were relatively low. No significant difference was found in the drug resistance rate of NTM strain against nine antituberculosis drugs in 5 years (P > 0.05).

conclusionsThe immune level of patients coinfected with HIV and NTM is low in advanced AIDS stage; more male are affected in patients who are mainly infected with MAC and M. kansasii and with serious drug resistance. The drug resistance rate of ethambutol and clarithromycin is relatively low.

Indexed as

Acquired Immunodeficiency SyndromeAdultAgedAged, 80 and overAntitubercular AgentsChinaClarithromycinEthambutolFemaleHIV-1HIV InfectionsHumansIsoniazidMaleMiddle AgedMycobacterium avium ComplexAntitubercular AgentsClarithromycinEthambutolIsoniazidRifampinStreptomycin

Identifiers

PMID30925547
PMCPMC6629352
OpenAlexW2931017095

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.